ALA
AROVELLA THERAPEUTICS LIMITED
$0.0570
▲ +3.64%
Market cap
$69M
Turnover
$144,958
Last price
$0.0570
Day change
+3.64%
Announcements
10
Range, past year
Open 0.096 · Low 0.046 · Now 0.057 · High 0.130
Open ALA in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ALA momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
42/100
Wyckoff phase
Downtrend21d
Trend stage
Neutral
1 Day
+3.6%
1 Week
+21.3%
1 Month
-5.0%
1 Year
-39.4%
RSI
59
Avg daily range
4.9%
AROVELLA THERAPEUTICS LIMITED scores 42 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Downtrend, where it has been for 21 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads moderate.
What stands out
- Volume 1.5× 60-day avg
- RSI in healthy zone (59)
- Near-term opportunity score 83
Points to watch
- 60d drawdown -27.7%
- Risk rating: High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsALA announcements
Recent price-sensitive releases.
- 2026-10-07 Second Clinical Batch Released for Immediate Patient Use Progress Report
- 2026-10-01 The path to first patient dosing Progress Report
- 2026-09-07 Clinical manufacturing batch released, first site activated Progress Report
- 2026-08-20 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-27 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-05-07 Arovella Appoints Acting CEO
- 2026-05-04 Board Refresh and CEO Resignation
More Health Care stocks
Most traded in the same sector.